NCT04566393 2026-01-28
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
xCures
University of California, San Francisco
St. Jude Children's Research Hospital
Peking University Cancer Hospital & Institute